24 February 2026
24 February 2026
Of the 390 patients enrolled, 197 received seralutinib and 193 received placebo.
Outside the US, over 200,000 patients have received the Smart Capsule.
Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.
Synicem hold CE marking and full regulatory approval for use in the UK.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
